NEW YORK, Feb.  05, 2026  (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE:DSS) (the &#34;Company&#34;), a multinational company operating across diverse industries including product packaging, biotechnology, commercial lending, and

DSS, Inc. Announces Closing of $1.0 Million Underwritten Public Offering

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>NEW YORK, Feb.  05, 2026  (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE:DSS) (the &amp;#34;Company&amp;#34;), a multinational company operating across diverse industries including product packaging, biotechnology, commercial lending, and</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>DSS, Inc. successfully closed a public offering generating around $1 million in proceeds. The funds will be allocated for general corporate purposes, enhancing its strategic operations across its diverse business lines.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>DSS closed a public offering, raising approximately $1 million.</li><li>Offering comprised 900,000 shares priced at $1.00 each.</li><li>Aegis Capital Corp. manages the offering as underwriter.</li><li>Proceeds will be used for general corporate purposes.</li><li>Company models focus on developing high-growth subsidiaries.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>DSS, Inc. (DSS)</strong>: Utilizing funds for corporate purposes may impact growth.</li><li><strong>Aegis Capital Corp. (N/A)</strong>: Acting as underwriter highlights confidence in DSS&#039;s market potential.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>The article fits under &#039;Corporate Developments&#039; due to the significant equity offering, indicating DSS&#039;s intent to secure funding for growth initiatives. This could signal ongoing strategic evolution within the company and attract investor interest.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>DSS raised $1 million, indicating potential growth opportunities.</li><li>Overallotment option allows Aegis to buy up to 135,000 additional shares.</li><li>Successful fundraising may enhance investor confidence in DSS&#039;s strategic plans.</li><li>Use of proceeds for working capital could improve operational efficiency.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>DSS raised gross proceeds of $1.0 million.</li><li>The offering consisted of 900,000 shares at $1.00 each.</li><li>Aegis Capital Corp. is the sole book-running manager.</li><li>The offering was made under effective shelf registration statement No. 333-281974.</li><li>Offering documents will be available on the SEC&#039;s website.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Consider buying DSS shares as funding could bolster growth initiatives in the medium term.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p align="justify">NEW YORK, Feb.  05, 2026  (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/quote/DSS">DSS</a>) (the "Company"), a multinational company operating across diverse industries including product packaging, biotechnology, commercial lending, and securities and investment management, today announced the closing of its previously announced firm commitment underwritten public offering. Gross proceeds to the Company were approximately $1.0 million, before deducting underwriting fees and other offering expenses payable by the Company.</p>  <p align="justify">The offering consisted of 900,000 shares of common stock. The public offering price per share of common stock was $1.00. In addition, the Company granted Aegis Capital Corp., the underwriter, an overallotment option to purchase up to an additional 135,000 shares of common stock, representing 15% of the number of shares sold in the offering solely to cover over-allotments, if any.</p>  <p align="justify">The Company expects to use the net proceeds from the offering for general corporate purposes, including working capital.</p>  <p align="justify"><strong>Aegis Capital Corp. acted as the sole book-running manager for the offering. Sichenzia Ross Ference Carmel LLP acted as counsel to the Company. Kaufman &amp; Canoles, P.C. acted as counsel to Aegis Capital Corp.</strong></p>  <p align="justify">The offering was made pursuant to an effective shelf registration statement on Form S-3 (No. 333-281974) previously filed with the U.S. Securities and Exchange Commission (SEC) on October 31, 2024, and declared effective by the SEC on November 5, 2024. A final prospectus supplement and accompanying prospectus describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC's website located at <u><a href="https://www.globenewswire.com/Tracker?data=vj6WqpMc3Ke0kxntLm4I0CdqX5FzQWaYLGlkpk1F4zRH7XD9meJ_pXK-C-St5wlVpBo40nG57Rfrpa2oxf2IBA==" rel="nofollow" target="_blank">www.sec.go</a>v</u>. Electronic copies of the final prospectus supplement and the accompanying prospectus may be obtained, when available, by contacting Aegis Capital Corp., Attention: Syndicate Department, 1345 Avenue of the Americas, 27th floor, New York, NY 10105, by email at <a href="mailto:syndicate@aegiscap.com">syndicate@aegiscap.com</a>, or by telephone at +1 (212) 813-1010.</p>  <p align="justify">This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</p>  <p align="justify"><strong>About DSS, Inc.</strong></p>  <p align="justify">DSS, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/quote/DSS">DSS</a>) is a multinational company operating across multiple business lines including product packaging, biotechnology, commercial lending, and securities and investment management. The Company operates a business model based on developing high-growth subsidiaries and unlocking value through strategic IPOs and public listings. For more information, visit <a href="http://www.dssworld.com" title="www.dssworld.com">www.dssworld.com</a>.</p>  <p align="justify"><strong>Forward-Looking Statements</strong></p>  <p align="justify">The foregoing material may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the Company's product development and business prospects, and can be identified by the use of words such as "may," "will," "expect," "project," "estimate," "anticipate," "plan," "believe," "potential," "should," "continue" or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of risks and uncertainties that could significantly affect current plans. Should one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.</p>  <p align="left"><em>For investor and media inquiries or additional information, please contact</em>:<br></br><br></br><strong>Investor Contact</strong>:<br></br><br></br>DSS, Inc.<br></br>Investor Relations<br></br>ir@dssworld.com<br></br>+1 (585) 565-2422</p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTY0OTY4MCM3NDExNTY0IzIwOTM3MzE="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/YTI5NTc0ZDMtOGIzZC00YmZhLThkN2UtNjYwOTQ3ZWZjNjk2LTExMDUzMDItMjAyNi0wMi0wNS1lbg==/tiny/DSS-Inc-.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/ce96f659-56dd-4218-a734-62efad33d7db"><img src="https://ml.globenewswire.com/media/ce96f659-56dd-4218-a734-62efad33d7db/small/newest-dss-logo1-png.png" border="0" width="150" height="84" alt="Primary Logo"></img></a></p>

DSS, Inc. successfully closed a public offering generating around $1 million in proceeds. The funds will be allocated for general corporate purposes, enhancing its strategic operations across its diverse business lines.

DSS, Inc. Announces Closing of $1.0 Million Underwritten Public Offering

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News